1. Scrip

CVS CEO Merlo On COVID-19 Vaccination: "Think Of It Like Booking A Travel Ticket"

 
• By Jessica Merrill

The pharmacy will be ready to begin COVID-19 vaccinations 48 hours after receiving the vaccine, Merlo said, outlining plans for a mass vaccination effort that will include online appointments.

Close up of a Doctor making a vaccination in the shoulder of patient,
CVS is preparing a mass COVID-19 vaccination plan • Source: Shutterstock

CVS Health Corp. CEO Larry Merlo outlined initial plans for a mass COVID-19 vaccination effort at the Forbes virtual Healthcare Summit on 2 December, including how the pharmacy plans to meet the thermal cold-chain demands required for Pfizer’s COVID-19 vaccine and book vaccination appointments for the general public.

"Our goal is to be ready to go 48 hours after we take receipt of the vaccine," Merlo said. "We...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

In Brief: Bayer Commits Up To $1.3bn For Kumquat’s KRAS G12D Inhibitor

 
• By Mary Jo Laffler

Deal Snapshot: Bayer will take over development of the asset once Kumquat completes a Phase Ia clinical trial, but the biotech firm may opt in to share US profits and losses.

S&E In Brief: Launch Updates And Political Headwinds

 
• By Sushmita Panda

Madrigal and Syndax update investors on their key launches, while Merck KGaA weighs in on the possibility of direct-to-consumer sales in the US.

Another Day Another Win For Novartis’s Ianalumab – This Time In ITP

 
• By Aakash Babu

The Swiss drugmaker’s BAFF-R inhibitor and ADCC-mediated B-cell depletor candidate has chalked up another win in late-stage development, further strengthening its pipeline-in-a-product bid.